Oral delivery of siRNA and antisense oligonucleotides

References

• Agrawal S, Zhang XS, Lu ZH, Zhao H, Tamburin JM, Yan YM, Cai HY, Diasio RB, Habus I, Jiang ZW, Iyer RP, Yu D, Zhang RW. (1995). Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral-administration. Biochem Pharmacol, 50(4), 571–576.
   PubMed Web of Science ®Google Scholar
• Aigner A. (2008). Cellular delivery in vivo of siRNA-based therapeutics. Curr Pharm Des, 14(34), 3603–3619. [Review]
   PubMed Web of Science ®Google Scholar
• Akhtar S. (2006). Non-viral vectors for gene therapy: beyond delivery. Gene Ther, 13, 739–740.
   PubMedGoogle Scholar
• Akhtar S, Benter IF. (2007a, December). Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest, 117(12), 3623–3632.
   PubMed Web of Science ®Google Scholar
• Akhtar S, Benter I. (2007b, March 30). Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. Adv Drug Deliv Rev, 59(2–3), 164–182.
   PubMed Web of Science ®Google Scholar
• Akhtar S, Hughes MD, Khan A, Bibby M, Hussain M, Nawaz Q, Double J, Sayyed P. (2000). The delivery of antisense therapeutics. Adv Drug Deliv Rev, 44(1), 3–21.
   PubMed Web of Science ®Google Scholar
• Aouadi M, Tesz GJ, Nicoloro SM, Wang M, Chouinard M, Soto E, Ostroff GR, Czech MP. (2009, April 30). Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature, 458(7242), 1180–1184.
   PubMed Web of Science ®Google Scholar
• Beale G, Hollins AJ, Benboubetra M, Sohail M, Fox SP, Benter I, Akhtar S. (2003, August). Gene silencing nucleic acids designed by scanning arrays: anti-EGFR activity of siRNA, ribozyme and DNA enzymes targeting a single hybridization-accessible region using the same delivery system. J Drug Target, 11(7), 449–456.
   PubMed Web of Science ®Google Scholar
• Bertrand JR, Pottier M, Vekris A, Opolon P, Maksimenko A, Malvy C. (2002, August 30). Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun, 296(4), 1000–1004.
   PubMed Web of Science ®Google Scholar
• Corr SC, Gahan CC, Hill C. (2008, January). M-cells: origin, morphology and role in mucosal immunity and microbial pathogenesis. FEMS Immunol Med Microbiol, 52(1), 2–12.
   PubMed Web of Science ®Google Scholar
• Costanotto D, Rossi JJ. (2009). The promises and pitfalls of RNA-interference-based therapeutics. Nature, 457(7228), 426–433.
   PubMed Web of Science ®Google Scholar
• Fattal E, Bochot A. (2008, December 8). State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriers. Int J Pharm, 364(2), 237–248.
   PubMedGoogle Scholar
• Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature, 391, 806–811.
   PubMed Web of Science ®Google Scholar
• Florence AT. (2004, February). Issues in oral nanoparticle drug carrier uptake and targeting. J Drug Target, 12(2), 65–70. [Review]
   PubMed Web of Science ®Google Scholar
• González Ferreiro M, Tillman LG, Hardee G, Bodmeier R. Alginate/poly-L-lysine microparticles for the intestinal delivery of antisense oligonucleotides. Pharm Res. 2002 Jun;19(6):755–64.
   PubMed Web of Science ®Google Scholar
• Gilmore IR, Fox SP, Hollins AJ, Akhtar S. Delivery strategies for siRNA-mediated gene silencing. Curr Drug Deliv. 2006 Apr;3(2):147–5. [Review]
   PubMedGoogle Scholar
• Hollins AJ, Omidi Y, Benter IF, Akhtar S. (2007, January). Toxicogenomics of drug delivery systems: exploiting delivery system-induced changes in target gene expression to enhance siRNA activity. J Drug Target, 15(1), 83–88.
   PubMed Web of Science ®Google Scholar
• Hughes MD, Hussain M, Nawaz Q, Sayyed P, Akhtar S. (2001). The cellular delivery of antisense oligonucleotides and ribozymes. Drug Discov Today, 6(6), 303–315.
   PubMed Web of Science ®Google Scholar
• Hussain N, Jaitley V, Florence AT. (2001, August 23). Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. Adv Drug Deliv Rev, 50(1-2), 107–142.
   PubMed Web of Science ®Google Scholar
• Judge AD, Sood V, Shaw JR, Fang D, McClintock K, Maclachlan I. (2005). Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol, 23(4), 457–462.
   PubMed Web of Science ®Google Scholar
• Juliano R, Alam MR, Dixit V, Kang H. (2008, July). Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res, 36(12), 4158–4171.
   PubMed Web of Science ®Google Scholar
• Kabanov AV. (2006, December 30). Polymer genomics: an insight into pharmacology and toxicology of nanomedicines. Adv Drug Deliv Rev, 58(15), 1597–1621.
   PubMed Web of Science ®Google Scholar
• Khan A, Benboubetra M, Sayyed PZ, Ng KW, Fox S, Beck G, Benter IF, Akhtar S. (2004). Sustained polymeric delivery of gene silencing antisense ODNs, siRNA, DNAzymes and ribozymes: in vitro and in vivo studies. J Drug Target, 12(6), 393–404.
   PubMed Web of Science ®Google Scholar
• Kindrachuk J, Potter J, Wilson HL, Griebel P, Babiuk LA, Napper S. (2008, June). Activation and regulation of toll-like receptor 9: CpGs and beyond. Mini Rev Med Chem, 8(6), 590–600.
   PubMed Web of Science ®Google Scholar
• Kleinman ME, Yamada K, Takeda A, Chandrasekaran V, Nozaki M, Baffi JZ, Albuquerque RJ, Yamasaki S, Itaya M, Pan Y, Appukuttan B, Gibbs D, Yang Z, Karikó K, Ambati BK, Wilgus TA, DiPietro LA, Sakurai E, Zhang K, Smith JR, Taylor EW, Ambati J. (2008, April 3). Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature, 452(7187), 591–597.
   PubMed Web of Science ®Google Scholar
• Krishnamachari Y, Salem AK. (2009, March). Innovative strategies for co-delivering antigens and CpG oligonucleotides. Adv Drug Deliv Rev, 61(3), 205–217.
   PubMed Web of Science ®Google Scholar
• Kurreck J. (2009). RNA interference: from basic research to therapeutic applications. Angew Chem Int Ed Engl, 48(8), 1378–1398.
   PubMed Web of Science ®Google Scholar
• McMinn LH, Hodges GM, Carr KE. Gastrointestinal uptake and translocation of microparticles in the streptozotocin-diabetic rat. J Anat. 1996 Dec;189 ( Pt 3):553–9.
   PubMedGoogle Scholar
• Omidi Y, Hollins AJ, Benboubetra M, Drayton R, Benter IF, Akhtar S. (2003, July). Toxicogenomics of non-viral vectors for gene therapy: a microarray study of lipofectin- and oligofectamine-induced gene expression changes in human epithelial cells. J Drug Target, 11(6), 311–323.
   PubMed Web of Science ®Google Scholar
• Omidi Y, Hollins AJ, Drayton RM, Akhtar S. (2005, August). Polypropylenimine dendrimer-induced gene expression changes: the effect of complexation with DNA, dendrimer generation and cell type. J Drug Target, 13(7), 431–443.
   PubMed Web of Science ®Google Scholar
• Raoof AA, Ramtoola Z, McKenna B, Yu RZ, Hardee G, Geary RS. (2002, November). Effect of sodium caprate on the intestinal absorption of two modified antisense oligonucleotides in pigs. Eur J Pharm Sci, 17(3), 131–138.
   PubMed Web of Science ®Google Scholar
• Raoof AA, Chiu P, Ramtoola Z, Cumming IK, Teng C, Weinbach SP, Hardee GE, Levin AA, Geary RS. (2004, June). Oral bioavailability and multiple dose tolerability of an antisense oligonucleotide tablet formulated with sodium caprate. J Pharm Sci, 93(6), 1431–1439.
   PubMed Web of Science ®Google Scholar
• Reischl D, Zimmer A. (2009, March). Drug delivery of siRNA therapeutics: potentials and limits of nanosystems. Nanomedicine, 5(1), 8–20.
   PubMed Web of Science ®Google Scholar
• Robbins M, Judge A, Maclachlan I. (2009, May 14). siRNA and innate immunity. Oligonucleotides. [Epub ahead of print]
   Google Scholar
• Sioud M. (2009). Deciphering the code of innate immunity recognition of siRNAs. Methods Mol Biol, 487, 41–59.
   PubMedGoogle Scholar
• Tillman LG, Geary RS, Hardee GE. (2008). Oral delivery of antisense oligonucleotides in man. J Pharm Sci, 97(1), 225–236.
   PubMed Web of Science ®Google Scholar
• Vlassov VV, Karamyshev VN, Yakubov LA. (1993). Penetration of oligonucleotides into mouse organism through mucosa and skin. FEBS Lett, 327(3), 271–274.
   PubMed Web of Science ®Google Scholar
• Whitehead KA, Langer R, Anderson DG. (2009, February). Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov, 8(2), 129–138. [Review]
   PubMed Web of Science ®Google Scholar
• Woodrow KA, Cu Y, Booth CJ, Saucier-Sawyer JK, Wood MJ, Mark Saltzman W. (2009, May 3). Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat Mater. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar